1. Home
  2. NMM vs NVCR Comparison

NMM vs NVCR Comparison

Compare NMM & NVCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Navios Maritime Partners LP

NMM

Navios Maritime Partners LP

HOLD

Current Price

$81.35

Market Cap

2.1B

ML Signal

HOLD

Logo NovoCure Limited

NVCR

NovoCure Limited

HOLD

Current Price

$15.06

Market Cap

2.0B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NMM
NVCR
Founded
2007
2000
Country
Greece
Switzerland
Employees
N/A
N/A
Industry
Marine Transportation
Medical/Dental Instruments
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.1B
2.0B
IPO Year
2007
2015

Fundamental Metrics

Financial Performance
Metric
NMM
NVCR
Price
$81.35
$15.06
Analyst Decision
Strong Buy
Buy
Analyst Count
1
6
Target Price
$85.00
$28.08
AVG Volume (30 Days)
93.1K
1.8M
Earning Date
05-05-2026
04-30-2026
Dividend Yield
0.34%
N/A
EPS Growth
N/A
21.79
EPS
N/A
N/A
Revenue
N/A
$655,353,000.00
Revenue This Year
$5.57
$7.72
Revenue Next Year
$3.66
$6.74
P/E Ratio
$7.24
N/A
Revenue Growth
N/A
8.28
52 Week Low
$41.66
$9.82
52 Week High
$80.97
$21.45

Technical Indicators

Market Signals
Indicator
NMM
NVCR
Relative Strength Index (RSI) 64.12 44.54
Support Level $69.21 $14.85
Resistance Level $80.69 $15.46
Average True Range (ATR) 2.50 1.12
MACD 0.53 -0.16
Stochastic Oscillator 79.97 3.67

Price Performance

Historical Comparison
NMM
NVCR

About NMM Navios Maritime Partners LP

Navios Maritime Partners LP is an international owner and operator of dry cargo and tanker vessels. Its vessels are generally chartered-out under short-term, medium-term and long-term time charters with an average remaining charter duration of approximately 2.1 years to a group of counterparties. Its fleet consisted of dry bulk vessels, containerships and tanker vessels, including two newbuilding capesize vessels, newbuilding containerships and newbuilding tankers. It operates in single segment.

About NVCR NovoCure Limited

NovoCure Ltd is an oncology company with a proprietary platform technology in the United States. Its business involves the development, manufacture, and commercialization of Tumor Treating Fields (TTFields) devices, including Optune Gio and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Trident, Lunar-2, Panova-3, Metis, and other products and technologies for the treatment of Glioblastoma, Non-small cell lung cancer, and Pancreatic cancer. Geographically, the company derives the majority of its revenue from the United States and the rest from Germany, Japan, and other markets.

Share on Social Networks: